EFFECT OF THE NEW STEROID DRUG GESTOBUTANOIL FOR HORMONE REPLACEMENT THERAPY OF GESTAGENOUS INSUFFICIENCY ON THE DEVELOPMENT OF FETUS AND OFFSPRING IN EXPERIMENTS ON RATS

Cover Page

Cite item

Full Text

Abstract

A study of the embryo- and fetotoxic effects registered in the antenatal and postnatal periods of development after the intragastric administration of Gestobutanoil in two doses (equitherapeutic and 10 times higher) has been performed.
It has been found that the introduction of gestagen Gestobutanoil in both doses did not affect the body weight of pregnant animals, which continued to increase progressively during pregnancy. The embryotropic effect of gestagen was revealed to be dose-dependent. The introduction of gestagen in a dose of 0.25 mg / kg (calculated equitherapeutic dose) had no adverse effect on the development of the embryo and fetus of rats. The gestagen in a dose of 2.5 mg / kg (10 equitherapeutic dose) had a negative effect on the course of pregnancy, which has been manifested by a statistically significant increase in preimplantation death and total fetal mortality, as well as a statistically significant decrease in the number of fetuses.
It has been shown that intragastric administration of Gestobutanoil in doses of 0.25 and 2.5 mg / kg to female rats from the 6th to the 19th days of pregnancy did not adversely affect the early development of the first generation offspring (postnatal mortality, body mass dynamics, and development of rats’ sensory-motor reflexes).

About the authors

N. I. Sheina

N.I. Pirogov Russian National Research Medical University, 119997, Moscow

Author for correspondence.
Email: ni_sheina@mail.ru
Шеина Наталья Ивановна (Sheina Natalya Ivanovna), доктор биологических наук, профессор кафедры гигиены Russian Federation

V. A. Parshin

N.I. Pirogov Russian National Research Medical University, 119997, Moscow

Email: vaparshin@mail.ru
Паршин Валерий Александрович (Parshin Valeri Alexandrovich), кандидат медицинских наук, старший научный сотрудник НИЛ молекулярной фармакологии Russian Federation

T. A. Fedotcheva

N.I. Pirogov Russian National Research Medical University, 119997, Moscow; All-Russian Research Institute of Medicinal and Aromatic Plants, 117216, Moscow

Email: tfedotcheva@mail.ru
Федотчева Татьяна Александровна (Fedotcheva Tatiana Alexandrovna), доктор медицинских наук, главный научный сотрудник НИЛ молекулярной фармакологии Russian Federation

N. L. Shimanovsky

N.I. Pirogov Russian National Research Medical University, 119997, Moscow

Email: shimannn@yandex.ru
Шимановский Николай Львович (Shimanovsky Nikolai L’vovich), член-корреспондент РАН, доктор медицинских наук, заведующий НИЛ молекулярной фармакологии Russian Federation

References

  1. Christian M.S., Brent R.L., Calda P. Embryo-fetal toxicity signals for 17 alphahydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins. J Matern Fetal Neonatal Med. 2007, 20(2), 89-112.
  2. Barrow P. Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2016 and 2017. Reprod Toxicol. 2018, 80, 117-125 (doi: 10.1016/j.reprotox.2018.04.008).
  3. FDA database (2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021778s018lbl.pdf.
  4. Jordan A. Toxicology of depot medroxyprogesterone acetate. Contraception. 1994, 49, 189-201.
  5. Heffron R., Achilles S.L., Dorflinger L.J., Hapgood J.P., Kiarie J., Polis C.B., Steyn P.S. Pharmacokinetic, biologic, and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women. Contraception. 2018. pii: S0010-7824(18)30524-9 (doi: 10.1016/j.contraception.2018.12.001).
  6. Schardein J.L, Birch R., Hesley R., Thorsrud B.A. Multigeneration reproductive study of hydroxyprogesterone caproate (HPC) in the rat: laboratory results and clinical significance. Birth Defects Res B Dev. Reprod. Toxicol. 2012, 95(2), 160-174 (doi: 10.1002/bdrb.21000).
  7. Van Diepen H.A. Preclinical pharmacological profile of nomegestrol acetate, a synthetic 19-nor-progesterone derivative. Reprod. Biol. Endocrinol. 2012, 8, 10, 85 (doi: 10.1186/1477-7827-10-85).
  8. Merck Sharp and Dohme Limited Summary of Product Characteristics: Zoely 2.5 mg/1.5 mg film-coated tablets. Electronic Medicines Compendium (eMC) 2011. Available from: http://www.medicines.org.uk/emc/medicine/27581/SPC/.
  9. Sheina N.I., Parshin V.A., Rybakov U.L., Gukasov V.M., Kostiaeva M.G., Semeikin A.V., Fedotcheva T.A., Shimanovsky N.L. Evaluation of the toxicity of new progestogen gestobutanoil in an experiment on rats and mice. Experimental and Clinical Pharmacology. 2018, 81(11), 18-25 (in Russian).
  10. Guidelines for the study of reproductive toxicity of drugs. Compilers: Durnev A.D., Smol’nikova N.M., Skosyreva A.M. etc. / in the «Guidelines for preclinical studies of pharmaceuticals» edited by Mironov A.N. etc. – M., 2012, 1, 80-94 (in Russian).
  11. Gus’kova T.A. Preclinical toxicological study of drugs as a guarantee of safety of their preclinical study. Toxicological Bulletin. 2010, 5, 2-6 (in Russian).
  12. Dyban A.P. Early development of mammals. L., Science, 1988, 228 p (in Russian).
  13. Kiryuschenkov L.P., Tarakhovsky M.L. Influence of drugs on the fetus. M., 1990, 286 p (in Russian).
  14. Amann R.P. Use of animal models for detecting specific alterations in reproduction. Fundam. Appl. Toxicol. 1982, 2, 13–16.
  15. Menegola E., Broccia M.L., Giavini E. Atlas of rat fetal skeleton double stained for bone and cartilage. Teratology. 2001, 64(3), 125–133.
  16. Neubert D. Reproductive toxicology: the science today. Teratogenesis, Carcinogenesis and Mutagenesis. 2002, 22, 159–174.
  17. Bailey N. Statistical methods in biology. M., Mir, 1963, 271 p (in Russian).
  18. Kuang Y., Chen Q., Fu Y., Wang Y., Hong Q., Lyu Q., Ai A., Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015, 104(1), 62-70 (doi: 10.1016/j.fertnstert.2015.03.022).
  19. Fedotcheva T.A., Shimanovsky N.L. The role of gestagens in the treatment of endometriosis. Problems of endocrinology. 2018, 64(1), 54-61 (in Russian). (doi: 10.14341/probl201864154-61).
  20. Polikarpova A.V., Levina I.S., Sigai N.V., Zavarzin I.V., Morozov I.A., Rubtsov P.M., Guseva A.A., Smirnova O.V., Shchelkunova T.A. Immunomodulatory effects of progesterone and selective ligands of membrane progesterone receptors. Steroids. 2019, 145, 5-18 (doi: 10.1016/j.steroids.2019.02.009).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Sheina N.I., Parshin V.A., Fedotcheva T.A., Shimanovsky N.L.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.